Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a Phase II study

Open access
Ajani, Jaffer A., Baker, Jackie, Pisters, Peter W. T., Ho, Linus, Mansfield, Paul F., Feig, Barry W., Charnsangavej, Chusilp·2002·Cancer

Abstract

BACKGROUND: This Phase II study assessed the response rate and toxicity profile of the combination CPT‐11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction. METHODS: Patients with histologic proof of adenocarcinoma of the stomach or the gastroesophageal junction with adequate liver, kidney, and bone marrow functions were treated with 65 mg/m 2 CPT‐11 plus 30 mg/m 2 cisplatin, both administered intravenously 1 day per week for 4 consecutive weeks, followed by a recovery period of 2 consecutive weeks. The response rate, time to disease progression, survival, and toxic effects were analyzed. RESULTS: Thirty‐six of 38 registered patients (95%) were assessable. The median number of 6‐week cycles per patient was 2.5 (range, 1–7 6‐week cycles). Four patients (11%) achieved a complete response, and 17 patients (47%) had a partial response for an overall response rate of 58%. The median time to progression of carcinoma was 24 weeks, and the median survival was 9 months (range, 1–23+ months). There was one treatment‐related death. Major toxic effects included diarrhea, neutropenia, and fatigue. Ninety percent of all planned doses were delivered on time; however, 53 of 79 canceled or delayed weekly doses (66%) occurred in the third or fourth week of the therapy cycle. CONCLUSIONS: The combination of CPT‐11 and cisplatin is active against gastric or gastroesophageal adenocarcinoma and needs to be studied further. A modification in doses and schedules may be warranted to make the regimen more tolerable to patients. The addition of other active drugs or radiation therapy to this regimen would be of interest. Cancer 2002;94:641–6. © 2002 American Cancer Society. DOI 10.1002/cncr.10279

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.10279

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 160

Metadata

Authors
Ajani, J. A., Baker, J., Pisters, P. W. T., Ho, L., Mansfield, P. F., Feig, B. W., & Charnsangavej, C.
Venue
Cancer
Publisher
Wiley
Published
2002-01-31
Volume
94
Issue
3
Pages
641-646
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1525737532
Cited by
160
References
1
FWCI
14.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a Phase II study. https://app.cochat.ai/papers/10.1002/cncr.10279
The paper
Ajani, J. A., Baker, J., Pisters, P. W. T., Ho, L., Mansfield, P. F., Feig, B. W., & Charnsangavej, C. (2002). CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a Phase II study. Cancer. https://doi.org/10.1002/cncr.10279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.